共 50 条
- [1] DareonTM-5: An open-label phase 2 trial of BI 764532, a DLL3-targeting T-cell engager, in patients (pts) with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomasCANCER RESEARCH, 2024, 84 (07)Gambardella, ValentinaGreystoke, AlastairReck, MartinLiu, MeiruoMueller, MarthaDuenzinger, UlrichBergsland, Emily B.Owonikoko, Taofeek
- [2] Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomasFUTURE ONCOLOGY, 2022, 18 (24) : 2639 - 2649Wermke, MartinFelip, EnriquetaGambardella, ValentinaKuboki, YasutoshiMorgensztern, DanielHamed, Zohra Oum'Liu, MeiruoStudeny, MatusOwonikoko, Taofeek K.
- [3] A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Wermke, MartinFelip, EnriquetaGambardella, ValentinaKuboki, YasutoshiMorgensztern, DanielHamed, Zohra Oum'Geng, JunxianStudeny, MatusOwonikoko, Taofeek K.
- [4] Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumours: Focus on neuroendocrine carcinomasANNALS OF ONCOLOGY, 2023, 34 : S499 - S500Gambardella, V.Castillon, J. CapdevilaKuboki, Y.Alese, O.Morgensztern, D.Sayehli, C. M.Sanmamed, M. F.Arriola, E.Hamed, Z. Oum'Song, E.Studeny, M.Wermke, M.
- [5] Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304).JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Paz-Ares, Luis G.Felip, EnriquetaAhn, Myung-JuBlackhall, Fiona HelenBorghaei, HosseinCho, Byoung ChulJohnson, Melissa LynneRamalingam, Suresh S.Reck, MartinZhang, AliciaJu, Chia-HsinMinocha, MukulMukherjee, SujoySuri, GauravJandial, DanielleBebb, D. Gwyn
- [6] DAREON™-7: A phase 1, open-label, dose escalation and expansion cohort trial of the delta-like ligand (DLL3)-targeting T-cell engager BI 764532, plus first-line platinum-based chemotherapy in patients with DLL3-positive (+) neuroendocrine carcinomasCANCER RESEARCH, 2024, 84 (07)Capdevila, JaumeVandamme, TimonNiccoli, PatriciaMishima, SaoriKato, KenMa, YiyuanSun, PingGeng, LijiangLauer, Ulrich M.
- [7] Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) plus ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3ANNALS OF ONCOLOGY, 2023, 34 : S1076 - S1077Mazieres, J.Duruisseaux, M.Curcio, H.Morizane, C.Galot, R.Rottey, S.Stratmann, J. A.Ma, Y.Bouzaggou, M.Geng, L.Wermke, M.
- [8] Impact of Brain Metastases on Safety and Efficacy of MK-6070, a DLL3-Targeting T Cell Engager, in Small Cell Lung CancerJOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S32 - S33Choudhury, N. J.Beltran, H.Johnson, M. L.Schenk, E. L.Sanborn, R. E.Thompson, J. R.Mamdani, H.Dowlati, A.Aggarwal, R. R.Gramza, A. W.Jain, P.
- [9] A PHASE 1 STUDY OF AMG 119, A DLL3-TARGETING, CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY, IN RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC)JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A728 - A728Byers, LaurenHeymach, JohnGibbons, DonZhang, JianjunChiappori, AlbertoRasmussen, ErikDecato, BenjaminSmit, Marie-AnneSadraei, Nooshin Hashemi
- [10] Phase 2 study of tarlatamab, a DLL3-targeting, half life-extended, bispecific T-cell engager (HLE BiTE) immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Ramalingam, Suresh S.Ahn, Myung-JuAkamatsu, HiroakiBlackhall, Fiona HelenBorghaei, HosseinHummel, Horst-DieterJohnson, Melissa LynneReck, MartinZhang, YiranJandial, DanielleCheng, SunfaPaz-Ares, Luis G.